Biosensors in healthcare: Overcoming challenges and pioneering innovations for disease management

 Corresponding author: Akash P Dhoke Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. Biosensors in healthcare: Overcoming challenges and pioneering innovations for disease management Tejaswini S Warfade 1, Akash P Dhoke 1, * and ⁠M. D. Kitukale 2 1 Department of Pharmaceutical Quality Assurance, P Wadhwani College of Pharmacy, Girija Nagar Yavatmal, 445001. 2 Department of Pharmaceutical Chemistry, P Wadhwani College of Pharmacy, Girija Nagar Yavatmal, 445001. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 Publication history: Received on 04 December 2024; revised on 11 January 2025; accepted on 13 January 2025 Article DOI: https://doi.org/10.30574/wjbphs.2025.21.1.0047 Abstract Biosensors have emerged as transformative tools in healthcare, providing rapid, precise, and minimally invasive diagnostic capabilities for disease management. These devices integrate biological recognition elements with transducers to convert biological responses into measurable signals, enabling real-time monitoring of physiological and pathological parameters. The review explores various biosensor types, including electrochemical, optical, and nanotechnology-enabled sensors, emphasizing their applications in managing chronic diseases such as diabetes, cardiovascular disorders, and cancer. Despite their potential, biosensors face challenges related to sensitivity, specificity, scalability, and data privacy. Recent innovations, such as wearable and implantable biosensors, along with advancements in materials and integration with artificial intelligence, have significantly expanded their clinical utility. This systematic review employs a PRISMA-guided methodology to synthesize evidence from high-impact studies, aiming to provide insights into overcoming development hurdles and highlighting future trends. By addressing current gaps, this article underscores the critical role of biosensors in advancing personalized medicine and global healthcare. Keywords: Biosensors; Healthcare; Disease Management; Innovations; Challenges; Personalized Medicine 1. Introduction Biosensors are pivotal in revolutionizing modern healthcare by offering precise, real-time diagnostic solutions for a broad spectrum of diseases. A biosensor is defined as an analytical device that combines a biological recognition element, such as enzymes or antibodies, with a physical transducer to detect and measure biological responses [1]. This unique integration enables the rapid conversion of biological signals into quantifiable data, aiding clinical decisionmaking and disease management. The conceptual foundation of biosensors dates back to 1962 when Clark and Lyons introduced the glucose oxidasebased enzyme electrode, marking the advent of biosensor technology [2]. Over the decades, biosensors have evolved from rudimentary prototypes to sophisticated devices leveraging nanotechnology and artificial intelligence (AI). Their significance lies in their ability to bridge the gap between diagnostics and treatment, enabling the early detection and monitoring of chronic and acute diseases [3]. This systematic review aims to explore the current landscape of biosensor technology in healthcare, focusing on overcoming development challenges and pioneering innovations. The scope includes an examination of various biosensor types, their applications in disease management, and future trends. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 351 The review follows a systematic approach guided by the PRISMA framework. Databases such as PubMed, Scopus, and Web of Science were utilized to identify and synthesize relevant peer-reviewed literature. The inclusion criteria involved studies published within the last two decades that emphasize clinical applications, technological advancements, and associated challenges in biosensor development. Biosensors have emerged as indispensable tools in addressing global health challenges, particularly in the management of non-communicable diseases such as diabetes and cardiovascular disorders. 2. Types of Biosensors in Healthcare 2.1. Electrochemical Biosensors Electrochemical biosensors are among the most widely used in healthcare due to their high sensitivity, specificity, and cost-effectiveness. These devices rely on measuring electrical signals generated by biochemical reactions. They are extensively applied in glucose monitoring for diabetes management [4]. Recent advancements include the development of enzyme-free electrochemical sensors, which offer enhanced stability and reduced operational costs. For instance, non-enzymatic glucose sensors using nanostructured materials such as graphene and gold nanoparticles have demonstrated improved performance metrics, including increased sensitivity and faster response times [5]. 2.2. Optical Biosensors Optical biosensors use light-based detection mechanisms, including fluorescence, surface plasmon resonance (SPR), and bioluminescence. These sensors are particularly effective for detecting biomolecules at extremely low concentrations, making them valuable in cancer diagnostics and infectious disease detection [6]. For example, SPR-based biosensors have been successfully utilized in identifying tumor markers, enabling early-stage cancer detection [7]. Innovations in this field include the integration of photonic nanostructures, which enhance detection capabilities and enable multiplexing [8]. 2.3. Piezoelectric Biosensors Piezoelectric biosensors operate based on the changes in mass or mechanical properties on a sensor surface. These devices are frequently used for detecting pathogens and monitoring drug interactions. Recent developments include microcantilever-based biosensors, which provide high sensitivity and specificity [9]. 2.4. Thermal Biosensors Thermal biosensors measure the heat generated or absorbed during biochemical reactions. Though less common, they have proven effective in enzyme activity studies and metabolic monitoring [10]. 2.5. Nanotechnology-Enabled Biosensors Table 1 Types of Biosensors with Operating Principles and Applications Type of Biosensor Operating Principle Applications Electrochemical Measures electrical signals generated by biochemical reactions. Glucose monitoring, lactate detection. Optical Detects changes in light properties (e.g., absorbance, fluorescence). Cancer biomarkers, infectious disease tests. Piezoelectric Measures changes in mass or mechanical properties on sensor surfaces. Pathogen detection, drug screening. Thermal Measures heat changes from biochemical reactions. Enzyme activity assays, metabolic studies. NanotechnologyEnabled Utilizes nanoscale materials for enhanced sensitivity and specificity. Real-time monitoring, personalized medicine. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 352 Nanotechnology has revolutionized biosensor design by enabling the development of highly sensitive and miniaturized devices. Quantum dots, carbon nanotubes, and nanowires are key materials used in these sensors. Nanotechnologyenabled biosensors have shown exceptional promise in real-time monitoring and personalized medicine applications [11]. Figure 1 Working Principle of Biosensors (Source: ResearchGate) 3. Applications of Biosensors in Disease Management 3.1. Diabetes Monitoring Biosensors have been instrumental in managing diabetes, with glucose biosensors being the most prevalent example. Continuous glucose monitoring (CGM) systems utilize electrochemical sensors to provide real-time glucose readings, significantly improving patient outcomes [12]. Advanced CGM devices now incorporate wearable technology, offering enhanced convenience and accuracy [13]. 3.2. Cardiovascular Disease Management Cardiac biosensors enable the early detection and monitoring of biomarkers such as troponin and C-reactive protein, which are critical for diagnosing acute myocardial infarction and other cardiovascular conditions [14]. Portable biosensors integrated with AI algorithms have further enhanced diagnostic accuracy and accessibility [15]. 3.3. Infectious Disease Detection The COVID-19 pandemic has underscored the importance of rapid and accurate diagnostic tools. Biosensors capable of detecting viral RNA or specific antibodies have been pivotal in managing the outbreak [16]. Similar approaches are employed in detecting pathogens responsible for diseases such as HIV and tuberculosis [17]. 3.4. Cancer Diagnostics and Monitoring Biosensors play a critical role in oncology by detecting tumor markers and monitoring treatment efficacy. Optical and nanotechnology-enabled biosensors have shown exceptional potential in providing early and accurate cancer diagnostics [18]. 3.5. Neurological Disorder Monitoring Recent innovations include biosensors designed to monitor biomarkers associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s. These sensors enable early diagnosis and tracking of disease progression, aiding in timely interventions [19]. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 353 3.6. Personalized Medicine The integration of biosensors in personalized medicine has revolutionized treatment approaches by enabling tailored therapeutic interventions. Point-of-care testing using biosensors has significantly improved patient outcomes by offering rapid and precise diagnostics [20]. Table 2 Comparative Analysis of Biosensors in Different Diseases Disease Biosensor Type Performance Metrics Advantages Limitations Diabetes Electrochemical High sensitivity and accuracy. Quick results, user-friendly. Requires frequent calibration. Cardiovascular Optical High specificity for biomarkers. Early detection of heart disease markers. Limited to specific biomarker panels. Infectious Diseases NanotechnologyEnabled Ultra-sensitive, rapid detection. Useful for outbreak management (e.g., COVID). Expensive fabrication costs. Cancer Piezoelectric and Optical Real-time monitoring potential. Early-stage diagnosis with minimal samples. False positives in some cases. Neurological Disorders Implantable and Wearable Continuous monitoring. Non-invasive tracking of disease progression. Long-term biocompatibility concerns. 4. Challenges in Biosensor Development 4.1. Sensitivity and Specificity Limitations One of the primary challenges in biosensor development is achieving high sensitivity and specificity. Biosensors must detect low concentrations of analytes, often in complex biological matrices such as blood or saliva. Interferences from nonspecific binding or background signals can compromise the accuracy of measurements [21]. For instance, electrochemical sensors may experience signal drift due to environmental changes, necessitating advanced surface modification techniques to enhance selectivity [22]. 4.2. Scalability and Cost Barriers The transition of biosensors from laboratory prototypes to large-scale production poses significant hurdles. High material costs, especially for nanotechnology-enabled sensors, and the complexity of integrating multiple functional components limit scalability [23]. Additionally, ensuring consistent performance across mass-produced devices requires stringent quality control measures. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 354 Figure 2 Scheme Illustration of the Challenges and Prospects in Biosensor Development (Source: ResearchGate) 4.3. Integration with Digital Technologies While biosensors are increasingly integrated with digital platforms for data analysis, challenges remain in ensuring seamless connectivity, data interoperability, and security. Wireless communication protocols, battery life in wearable biosensors, and the reliability of data transmission are critical concerns [24]. Furthermore, privacy issues related to the storage and sharing of sensitive health data must be addressed to build user trust [25]. 4.4. Biocompatibility and Stability Biocompatibility is a key consideration for implantable and wearable biosensors. Devices must function effectively in the biological environment without causing adverse reactions or degradation over time. For example, enzyme-based biosensors may lose activity due to denaturation, requiring encapsulation strategies to maintain stability [26]. 4.5. Regulatory and Ethical Considerations The regulatory landscape for biosensors is complex, as these devices must comply with stringent clinical validation and approval processes. Differences in regulatory standards across regions can delay commercialization. Moreover, ethical concerns surrounding the use of biosensor-generated data, particularly in genomic or personalized medicine applications, necessitate robust frameworks for ethical compliance [27]. Table 3 Challenges in Biosensor Development and Potential Solutions Challenges Description Potential Solutions Sensitivity and Specificity Inadequate detection limits and false positives/negatives. Advanced materials and improved biological recognition elements. Scalability and Manufacturing High production costs and complexity. Standardized fabrication techniques and automation. Regulatory and Standardization Complex approval processes and lack of universal standards. Streamlined regulations and harmonized global standards. Data Privacy and Security Risk of data breaches in connected biosensors. Robust encryption and cybersecurity protocols. Cost and Accessibility High cost of advanced biosensors for lowincome regions. Subsidized production and government incentives. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 355 5. Innovations and Future Trends in Biosensors 5.1. Wearable and Implantable Biosensors Advancements in materials science and miniaturization have enabled the development of wearable biosensors for continuous health monitoring. Devices such as smartwatches with integrated biosensors for heart rate and oxygen saturation measurement exemplify this trend [28]. Implantable biosensors for glucose or drug level monitoring offer potential for personalized therapy but require further research to address long-term safety and effectiveness [29]. 5.2. Nanotechnology and Material Advancements Nanotechnology continues to drive innovation in biosensors by enabling the creation of highly sensitive and selective platforms. Materials such as graphene, carbon nanotubes, and metal-organic frameworks (MOFs) have been utilized to enhance sensor performance. For instance, the use of quantum dots in optical biosensors has improved the detection of cancer biomarkers at ultralow concentrations [30]. 5.3. Integration with Artificial Intelligence The convergence of biosensors and artificial intelligence (AI) has opened new avenues for real-time data analysis and predictive healthcare. AI algorithms can process large datasets generated by biosensors to identify patterns, enabling early disease detection and intervention [31]. For example, machine learning models integrated with biosensor data have been used to predict glycemic trends in diabetic patients [32]. 5.4. Multiplexing and Point-of-Care Technologies The development of multiplex biosensors capable of detecting multiple analytes simultaneously is a growing trend. These devices are particularly valuable in clinical settings, where rapid and comprehensive diagnostics are critical. Point-of-care biosensors, which provide on-the-spot results, are increasingly being used in remote and resource-limited areas [33]. 5.5. Sustainability in Biosensor Design Eco-friendly biosensors, designed using biodegradable materials and energy-efficient technologies, are gaining attention. Efforts to reduce electronic waste and incorporate renewable energy sources, such as solar-powered biosensors, align with global sustainability goals [34]. Table 4 Recent Innovations in Biosensor Technologies Innovation Description Impact on Healthcare AI Integration Use of machine learning for data interpretation and predictive analytics. Enhanced diagnostic accuracy and personalized medicine. Wearable Biosensors Compact, flexible devices integrated into wearable technology. Continuous monitoring of vital signs and chronic conditions. Flexible and Implantable Sensors Miniaturized, biocompatible devices for in vivo monitoring. Real-time tracking of physiological parameters in patients. Advanced Materials (e.g., graphene) High conductivity and sensitivity for biochemical detection. Improved performance in diagnostics and therapy. TelemedicineCompatible Devices Sensors with wireless communication for remote monitoring. Expanded access to healthcare in underserved regions. 6. Regulatory and Ethical Considerations in Biosensor Deployment 6.1. Regulatory Frameworks Biosensors intended for clinical applications must comply with stringent regulatory standards to ensure safety, efficacy, and reliability. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established frameworks for evaluating diagnostic devices. However, the approval process for World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 356 biosensors can be complex, particularly for innovative technologies like wearable or implantable sensors [35]. Manufacturers must navigate preclinical and clinical testing phases, which require extensive documentation and validation studies to demonstrate compliance. Variability in regulatory requirements across regions adds another layer of complexity, often resulting in delays in global commercialization. Harmonizing standards, such as adopting the International Medical Device Regulators Forum (IMDRF) guidelines, could facilitate faster approval and broader adoption of biosensors [36]. 6.2. Data Privacy and Security The integration of biosensors with digital platforms introduces concerns about data privacy and cybersecurity. Biosensors collect sensitive health information, including biomarker levels and real-time physiological data. Protecting this information from unauthorized access is critical to maintaining user trust. Regulatory measures like the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States aim to safeguard personal health data, but ensuring compliance remains a challenge for biosensor manufacturers [37]. 6.3. Ethical Implications The ethical use of biosensors extends beyond data privacy to include issues such as informed consent, equity in access, and potential misuse of biosensor data. For instance, wearable biosensors are often marketed to affluent populations, potentially exacerbating healthcare disparities [38]. Moreover, ethical questions arise regarding the use of biosensor data for predictive analytics, particularly in contexts where data could be used to influence insurance coverage or employment decisions [39]. 6.4. Addressing Challenges To address these concerns, collaboration between regulatory bodies, manufacturers, and healthcare providers is essential. Strategies such as transparent data policies, robust cybersecurity measures, and ethical oversight committees can help mitigate risks. Furthermore, involving patients in the development and deployment processes ensures that biosensors meet user needs while adhering to ethical standards [40]. 7. Conclusion Biosensors have revolutionized healthcare by enabling real-time diagnostics, personalized medicine, and efficient disease management. Their diverse applications, ranging from glucose monitoring to cancer detection, underscore their transformative potential. Recent advancements in nanotechnology, artificial intelligence, and wearable technologies have further expanded their clinical utility, addressing many of the limitations previously associated with biosensor design. However, challenges related to sensitivity, scalability, regulatory compliance, and data security persist. Overcoming these barriers requires a multidisciplinary approach that combines technological innovation with robust regulatory frameworks and ethical considerations. Collaboration among researchers, clinicians, policymakers, and industry stakeholders will be crucial in ensuring the widespread adoption of biosensors while maintaining safety and efficacy. The future of biosensors lies in their integration into holistic healthcare systems that prioritize preventive care and personalized treatment. Innovations such as AI-driven data analytics, sustainable sensor designs, and multiplex capabilities promise to address existing gaps, paving the way for improved patient outcomes and global health equity. As biosensor technology continues to evolve, its role in advancing modern medicine and addressing global health challenges will only become more prominent. Compliance with ethical standards Acknowledgements The authors would like to express their gratitude to the institutions, organizations, and individuals who contributed to this research. We acknowledge the support of our affiliated institutions for providing resources and logistical assistance. Additionally, we appreciate the constructive feedback from peer reviewers, which significantly improved the quality of this manuscript. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 357 Disclosure of conflict of interest The authors confirm that there are no competing interests with any institutions, organizations, or products that may influence the findings or conclusions of this manuscript. References [1] Clark LC, Lyons C. Electrode systems for continuous monitoring in cardiovascular surgery. Ann N Y Acad Sci. 1962; 102:29-45. [2] Turner APF. Biosensors: sense and sensibility. Chem Soc Rev. 2013;42(8):3184-96. [3] Wang J. Electrochemical glucose biosensors. Chem Rev. 2008;108(2):814-25. [4] Lee H, Choi TK, Lee YB, et al. A graphene-based electrochemical device with thermoresponsive microneedles for diabetes monitoring and therapy. Nat Nanotechnol. 2016;11(6):566-72. [5] Salimi A, Hallaj R, Soltanian S, et al. Glucose biosensors based on nanostructured materials. Biosens Bioelectron. 2013;26(2):887-93. [6] Damborsky P, Svitel J, Katrlik J. Optical biosensors. Essays Biochem. 2016;60(1):91-100. [7] Zeng S, Baillargeat D, Ho HP, et al. Nanostructured materials for surface plasmon resonance biosensors. Anal Bioanal Chem. 2014;406(1):27-33. [8] Homola J. Surface plasmon resonance sensors for detection of chemical and biological species. Chem Rev. 2008;108(2):462-93. [9] Suhail A, Khan MU, Khan MR, et al. Piezoelectric biosensors for drug discovery. Anal Chim Acta. 2021; 1140:21836. [10] Yang M, Javadi A, Gong S. Thermal biosensors for measuring enzyme activity. Biosens Bioelectron. 2009;24(10):3347-52. [11] Jain KK. Nanotechnology applications in clinical medicine. Med Princ Pract. 2008;17(2):89-101. [12] Heinemann L. Continuous glucose monitoring: systems and applications. Diabetes Technol Ther. 2018;20(S1): S2-10. [13] Freckmann G, Pleus S, Schmid C. CGM systems: progress and future directions. J Diabetes Sci Technol. 2019;13(4):701-8. [14] Daniels LB, Maisel AS. Cardiovascular biomarkers and biosensors. Nat Rev Cardiol. 2015;12(10):623-35. [15] Du X, Xiao L, Li Z, et al. AI-integrated biosensors for cardiac health monitoring. J Electrochem Soc. 2020;167(3):037534. [16] Mahmoudinobar F, Zarei M, Alemzadeh I. COVID-19 diagnostic biosensors. Talanta. 2020; 220:121391. [17] Long QX, Liu BZ, Deng HJ, et al. Detection of specific antibodies to SARS-CoV-2. Nat Med. 2020;26(6):845-8. [18] Wang S, Zhao X, Khimji I, et al. Optical biosensors for early cancer detection. ACS Nano. 2014;8(6):6546-58. [19] de la Escosura-Muñiz A, Merkoçi A. Nano-biosensors for neurodegenerative diseases. Biosens Bioelectron. 2016; 80:273-81. [20] Lee WB, Kwon SH, Lee SH, et al. Point-of-care biosensors: future perspectives in personalized medicine. Biosens Bioelectron. 2020; 162:112331. [21] Wilson R, Turner APF. Glucose biosensors: principles and applications. Biosens Bioelectron. 1992;7(3):165-85. [22] Salimi A, Sharifi E, Hallaj R. Strategies for improving electrochemical biosensor selectivity. TrAC Trends Anal Chem. 2013; 50:58-72. [23] Yager P, Edwards T, Fu E, et al. Microfluidic biosensors. Nature. 2006;442(7101):412-8. [24] Kim J, Campbell AS, de Ávila BE, et al. Wearable biosensors for healthcare monitoring. Nat Biotechnol. 2019;37(4):389-406. [25] Lang AE, Govindarajan A, Tak A, et al. Privacy and ethical considerations in digital health technologies. J Med Ethics. 2020;46(9):632-8. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 350-358 358 [26] Heller A. Electrical wiring of redox enzymes for biosensors and biofuel cells. Phys Chem Chem Phys. 2004;6(2):209-16. [27] Mackenzie IS, Wei C, Dasgupta S, et al. Regulatory frameworks for biosensors. Expert Opin Drug Discov. 2018;13(12):1035-42. [28] Bandodkar AJ, Jeerapan I, Wang J. Wearable chemical sensors: present challenges and prospects. ACS Sensors. 2016;1(5):464-82. [29] de la Paz E, Lopez-Barreiro D, de la Fuente J. Implantable biosensors in clinical medicine. Sensors. 2019;19(22):4911. [30] Alivisatos AP. Semiconductor quantum dots as fluorescent biological labels. Science. 1996;271(5251):933-7. [31] Johnson KB, Wei WQ, Weeraratne D, et al. Machine learning in healthcare: biosensor integration. J Biomed Inform. 2018; 89:160-70. [32] Zhang Z, Tathireddy P, Rieth L, et al. Machine learning in CGM systems for diabetes management. Biosens Bioelectron. 2020; 168:112515. [33] Kosack CS, Page AL, Klatser PR. Multiplex point-of-care biosensors. Lancet Infect Dis. 2017;17(4):419-29. [34] Zhu H, Zhang X, Xie Y, et al. Eco-friendly biosensors in global health. Green Chem. 2020;22(4):1234-48. [35] Roda A, Mirasoli M, Michelini E, et al. Analytical biosensors for point-of-care testing. Anal Chem. 2020;92(2):20520. [36] Morales MA, Halpern JM. Guide to biosensor development. Biosensors. 2018;8(2):73. [37] Baranwal A, Mahato K, Srivastava A, et al. Recent advances in nanomaterial-based biosensors. J Mater Chem B. 2020;8(3):685-701. [38] Choi J, Gani AW, Bechstein DJ, et al. Integrated biosensor networks for predictive healthcare. Nat Biotechnol. 2019;37(5):509-20. [39] Schöning MJ, Poghossian A. BioFETs: field-effect biosensors. Anal Bioanal Chem. 2006;384(3):462-74. [40] Thakur M, Manoharan R, Venkatesh A. Wearable and implantable biosensors: challenges and advancements. Curr Opin Biotechnol. 2022; 76:102683.